NEW YORK, Aug. 5, 2022 /PRNewswire/ -- The vaccine market size is set to grow by USD 28.28 billion from 2021 to 2026, progressing at a CAGR of 4.13% according to the latest forecast report by Technavio. The vaccines market is fragmented and the vendors are deploying growth strategies such as forming strategic alliances to increase their product offerings and geographical reach to compete in the market. Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BrightPath Biotherapeutics Co. Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson, and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Novavax Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., and Valneva SE are some of the major market participants.
To know about the vendor offerings - Request a FREE sample now!
Vaccines Market 2022-2026: Scope
Our vaccines market report covers the following areas:
Vaccines Market 2022-2026: Market Dynamics
Drivers - The increased funding for vaccine development and new vaccine launches, approval of vaccines, and a strong pipeline & increasing use of adjuvants in vaccines will offer immense growth opportunities.
Challenges - High cost of vaccine research, development, and manufacturing, product recalls, and safety concerns with respect to vaccination will challenge the growth of the market participants.
For detailed information on the market dynamics - Click Now!
Vaccines Market 2022-2026: Segmentation Analysis
Revenue Generating Segment -The vaccine market share growth in the prophylactic vaccines segment will be significant for revenue generation. There are different types of prophylactic vaccines, such as live attenuated vaccines, inactivated vaccines, recombinant vaccines, and toxoid vaccines.
Regional Highlights - 48% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for vaccines in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.
To know about the market contribution of each segment -Grab an Exclusive FREE Sample Report!
Vaccines Market 2022-2026: Key Highlights
CAGR of the market during the forecast period 2022-2026
Detailed information on factors that will assist vaccines market growth during the next five years
Estimation of the vaccines market size and its contribution to the parent market
Predictions on upcoming trends and changes in consumer behavior
The growth of the vaccines market
Analysis of the market's competitive landscape and detailed information on vendors
Comprehensive details of factors that will challenge the growth of vaccines market vendors
The competitive scenario provided in the Vaccines Market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.Don't wait, Make a strategic approach & boost your business goals with our Vaccines Market Forecast Report - Buy Now!
The sciatica treatment market share is expected to increase by USD 2.52 billion from 2021 to 2026, and the market's growth momentum will decelerate at a CAGR of 4.3%.
The throat cancer therapeutics market size is predicted to surge to USD 1.82 billion from 2021 to 2026 at a CAGR of 6.7%.
Vaccines Market Scope
Growth momentum & CAGR
Accelerate at a CAGR of 4.13%
Market growth 2022-2026
USD 28.28 billion
YoY growth (%)
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 48%
Key consumer countries
US, Canada, Germany, UK, and France
Leading companies, competitive strategies, consumer engagement scope
Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BrightPath Biotherapeutics Co. Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Novavax Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., and Valneva SE
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, and market condition analysis for the forecast period.
If our report has not included the data you are looking for, you can reach out to our analysts and get customized segments.
Browse for Technavio "Healthcare Market" Research Reports
Table Of Contents :
1 Executive Summary
1.1 Market overview
2 Market Landscape
2.1 Market ecosystem
3 Market Sizing
3.1 Market Definition
3.2 Market segment analysis
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
4 Five Forces Analysis
4.1 Five forces summary
4.2 Bargaining power of buyers
4.3 Bargaining power of suppliers
4.4 Threat of new entrants
4.5 Threat of substitutes
4.6 Threat of rivalry
4.7 Market condition
5 Market Segmentation by Type
5.1 Market segments
5.2 Comparison by Type
5.3 Prophylactic vaccines - Market size and forecast 2021-2026
5.4 Therapeutic vaccines - Market size and forecast 2021-2026
5.5 Market opportunity by Type
6 Customer Landscape
6.1 Customer landscape overview
7 Geographic Landscape
7.1 Geographic segmentation
7.2 Geographic comparison
7.3 North America - Market size and forecast 2021-2026
7.4 Europe - Market size and forecast 2021-2026
7.5 Asia - Market size and forecast 2021-2026
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
7.7 US - Market size and forecast 2021-2026
7.8 Germany - Market size and forecast 2021-2026
7.9 UK - Market size and forecast 2021-2026
7.10 Canada - Market size and forecast 2021-2026
7.11 France - Market size and forecast 2021-2026
7.12 Market opportunity by geography
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
8.4 Market trends
9 Vendor Landscape
9.2 Vendor landscape
9.3 Landscape disruption
9.4 Industry risks
10 Vendor Analysis
10.1 Vendors covered
10.2 Market positioning of vendors
10.3 Astellas Pharma Inc.
10.4 AstraZeneca Plc
10.5 Bavarian Nordic AS
10.6 Bharat Biotech Ltd.
10.7 BrightPath Biotherapeutics Co. Ltd.
10.8 CSL Ltd.
10.9 Daiichi Sankyo Co. Ltd.
10.10 Emergent BioSolutions Inc.
10.11 GlaxoSmithKline Plc
10.12 Gradalis Inc.
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
11.3 Currency conversion rates for US$
11.4 Research methodology
11.5 List of abbreviations
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View original content to download multimedia:https://www.prnewswire.com/news-releases/vaccines-market-to-grow-at-a-cagr-of-4-13-by-2026--evolving-opportunities-with-johnson-and-johnson--bharat-biotech-ltd---technavio-301600072.html